Evidence map›Paper›PMID 36459697›Full record

ArticleACS nano2022

Innate Immune Stimulation Using 3D Wireframe DNA Origami.

Rebecca R Du, Edward Cedrone, Anna Romanov, Reuven Falkovich, Marina A Dobrovolskaia, Mark Bathe

Open access · greenAbstract read
In one paragraph

Article in ACS nano, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 79 citations in OpenAlex.

  1. Programmable DNA Logic Systems for Applications in Biomedicine.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Programmable DNAzyme nanocatalysts for tumor immunometabolic modulation.Journal of Zhejiang University. Science. B · 2026
    Review
  3. DNA Nanostructures for siRNA Delivery.Bioconjugate chemistry · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Structural immunotherapy: Harnessing chemical design to build powerful next-generation therapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Plugging synthetic DNA nanoparticles into the central dogma of life.Chemical communications (Cambridge, England) · 2024
    Review
  19. Bottom-up synthetic immunology.Nature nanotechnology · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rebecca R DuDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts02139, United States.
Edward CedroneNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland21702, United States.
Anna RomanovDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts02139, United States.ORCID 0000-0002-1239-4946
Reuven FalkovichDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts02139, United States.
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland21702, United States.ORCID 0000-0002-4233-9227
Mark BatheDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts02139, United States.ORCID 0000-0002-6199-6855
Massachusetts Institute of Technology · USFrederick National Laboratory for Cancer Research · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI NILES, JACQUIN C · 1985 to 2020
$25.6M
Interdepartmental Biotechnology Training ProgramT32GM008334 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WITTRUP, KARL DANE · 1989 to 2018
$15.2M
Simultaneous profiling of neuronal synapse activities, proteins, and messenger RNAs at the single-cell levelR01MH112694 · NIMH · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Mark Bathe · 2017 to 2026
$2.8M
Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen PresentationR01AI162307 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Mark Bathe, Facundo Damian Batista · 2021 to 2026
$2.4M
Structured DNA Nanoparticles Therapeutic mRNA and CRISPR/Cas9 DeliveryR21EB026008 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BATHE, MARK · 2018 to 2021
$796k
NCI NIH HHS 75N91019D00024NIAID NIH HHS R01 AI162307NIBIB NIH HHS R21 EB026008NIEHS NIH HHS P30 ES002109NIGMS NIH HHS T32 GM008334NIMH NIH HHS R01 MH112694
6 · The paper itself

Abstract

Three-dimensional wireframe DNA origami have programmable structural and sequence features that render them potentially suitable for prophylactic and therapeutic applications. However, their innate immunological properties, which stem from parameters including geometric shape and cytosine-phosphate-guanine dinucleotide (CpG) content, remain largely unknown. Here, we investigate the immunostimulatory properties of 3D wireframe DNA origami on the TLR9 pathway using both reporter cell lines and primary immune cells. Our results suggest that bare 3D polyhedral wireframe DNA origami induce minimal TLR9 activation despite the presence of numerous internal CpG dinucleotides. However, when displaying multivalent CpG-containing ssDNA oligos, wireframe DNA origami induce robust TLR9 pathway activation, along with enhancement of downstream immune response as evidenced by increases in Type I and Type III interferon (IFN) production in peripheral blood mononuclear cells. Further, we find that CpG copy number and spatial organization each contribute to the magnitude of TLR9 signaling and that NANP-attached CpGs do not require phosphorothioate stabilization to elicit signaling. These results suggest key design parameters for wireframe DNA origami that can be programmed to modulate immune pathway activation controllably for prophylactic and therapeutic applications.

Indexed as

Leukocytes, MononuclearToll-Like Receptor 9DNADNA, Single-StrandedImmunity, InnateOligodeoxyribonucleotidesDNADNA, Single-StrandedOligodeoxyribonucleotidesToll-Like Receptor 93D wireframe DNA origamiCpGimmunomodulationimmunostimulationmultivalencyTLR9

Identifiers

PMID36459697
PMCPMC10144931
OpenAlexW4310581951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.